Gradalis Inc. Release: FANG™ Personalized Tumor Vaccine Stimulates Immune Response and More than Doubles Time to Recurrence in Patients with Advanced Stage Ovarian Cancer
5/16/2013 9:27:33 AM
More...
|
Gradalis Inc. Closes $24 Million in Series B Financing
1/3/2013 7:25:50 AM
More...
|
Baylor College of Medicine and Gradalis Inc. Enter Collaboration Agreement to Utilize Gradalis' Bifunctional shRNA Platform in Translational Medicine Research
7/11/2012 10:13:27 AM
More...
|
Gradalis Inc. Release: Study Published in Molecular Therapy Shows that Immune Response to FANG(TM) Personalized Cancer Therapeutic Correlates with Prolonged Survival in Patients with Advanced Stage Cancer
3/1/2012 10:37:27 AM
More...
|
Champions Biotechnology, Inc. (CSBR) Partners with Gradalis Inc. and Mary Crowley Cancer Research Center to Develop Personalized Vaccines for Cancer Patients
2/3/2009 9:37:01 AM
More...
|